Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02643550
Recruitment Status : Recruiting
First Posted : December 31, 2015
Last Update Posted : April 30, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Innate Pharma

Brief Summary:

The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1


Condition or disease Intervention/treatment Phase
Head and Neck Neoplasms Biological: Monalizumab Biological: Cetuximab Biological: Anti-PD(L)1 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Study Start Date : December 2015
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab

Arm Intervention/treatment
Experimental: Dose escalation
Dose escalation of monalizumab in combination with cetuximab
Biological: Monalizumab
Other Name: IPH2201

Biological: Cetuximab
Experimental: Expansion cohort 1
monalizumab + cetuximab expansion cohort
Biological: Monalizumab
Other Name: IPH2201

Biological: Cetuximab
Experimental: Expansion cohort 2
monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers
Biological: Monalizumab
Other Name: IPH2201

Biological: Cetuximab
Experimental: Expansion cohort 3
monalizumab + cetuximab + anti-PD(L)1
Biological: Monalizumab
Other Name: IPH2201

Biological: Cetuximab
Biological: Anti-PD(L)1



Primary Outcome Measures :
  1. Occurrence of Dose Limiting Toxicities (DLT) in the dose escalation part of the study [ Time Frame: within 4 weeks after first administration ]
    To assess the occurrence of Drug Limited Toxicities (DLTs)

  2. Objective Response Rate for expansion cohorts [ Time Frame: up to 12 months ]
    rate of patients in complete or partial response according to RECIST 1.1


Secondary Outcome Measures :
  1. Objective Response Rate for dose escalation part of the study [ Time Frame: up to 12 months ]
    rate of patients in complete or partial response according to RECIST 1.1

  2. Duration of Response for expansion cohorts [ Time Frame: From confirmed response until disease progression, up to 12 months ]
    Duration of complete and partial response

  3. Progression Free Survival for expansion cohorts [ Time Frame: Until disease progression or death, up to 2 years ]
    time between the start of treatment and the first documented progression or death

  4. Overall Survival for expansion cohorts [ Time Frame: Until death, up to 2 years ]
    time between the start of treatment and death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. Age ≥ 18 years
  2. Histologically or cytologically-confirmed, HPV (+) or HPV (-) squamous cell carcinoma of the nasopharynx (WHO Type 1), oropharynx, hypopharynx, larynx (supraglottis, glottis, subglottis) or oral cavity,
  3. Recurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination with measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1

For phase II cohorts:

  • Cohort #1: Patients who received a maximum of two prior systemic regimens for recurrent and/or metastatic disease and not amenable to further therapy with curative intent
  • Cohort #2: Patients with R/M SCCHN not amenable to therapy of curative intent,who have received a maximum of two prior systemic regimens in the R/M setting and who have received prior PD-(L)1 blockers
  • Cohort #3: Patients with R/M SCCHN who have not received prior systemic regimens in the R/M setting and who have not received prior PD-(L)1 inhibitors

Main Exclusion Criteria:

  1. For phase II cohort #1 and cohort #2: Patients who received more than 2 prior systemic regimens for recurrent and/or metastatic disease (no restriction in the phase Ib part of the trial).
  2. For phase II cohort #1 and cohort #2 : Patients who received cetuximab or another inhibitor of epidermal growth factor receptor are excluded from the phase II of the trial, except if cetuximab was given as part of a primary treatment approach, with no progressive disease for at least 4 months following the end of prior cetuximab treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02643550


Contacts
Layout table for location contacts
Contact: Agnes Boyer Chammard, MD +33430303120 Agnes.BOYER-CHAMMARD@innate-pharma.fr
Contact: Franceline Calmels +33430303062 Franceline.CALMELS@innate-pharma.fr

Locations
Layout table for location information
United States, California
Stanford Cancer Center Recruiting
Stanford, California, United States, 94305
Contact: Alexander Colevas, MD         
United States, Illinois
university of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Tanguy Lim-Seiwert, MD         
United States, New York
Icahn School of Medicine at Mount Sinaï Recruiting
New York, New York, United States, 10029
Contact: Marshall Posner, MD         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Roger Cohen, MD         
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Jessica Bauman, MD         
France
Centre Jean Perrin Recruiting
Clermont-Ferrand, France
Contact: Maureen Bernadach, MD         
Centre Oscar Lambret Recruiting
Lille, France
Contact: Gautier Lefebvre, MD         
Centre Leon Berard Recruiting
Lyon, France
Contact: Jerome Fayette, MD         
Hopital La Timone Recruiting
Marseille, France
Contact: Sebastien Salas, MD         
Institut Regional du Cancer de Montpellier Recruiting
Montpellier, France
Contact: Didier Cupissol, MD         
Centre Antoine Lacassagne Recruiting
Nice, France
Contact: Esma Saada Bouzid, MD         
Centre Eugene Marquis Recruiting
Rennes, France
Contact: Elodie Vauleon, MD         
ICO Rene Gauducheau Recruiting
Saint-Herblain, France
Contact: Frederic Rolland, MD         
Institut Gustave Roussy Recruiting
Villejuif, France
Contact: Caroline Even, MD         
Sponsors and Collaborators
Innate Pharma
AstraZeneca
Layout table for additonal information
Responsible Party: Innate Pharma
ClinicalTrials.gov Identifier: NCT02643550    
Other Study ID Numbers: IPH2201-203
First Posted: December 31, 2015    Key Record Dates
Last Update Posted: April 30, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Head and Neck Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Cetuximab
Antineoplastic Agents, Immunological
Antineoplastic Agents